Menu
Currency
GWAS Study

Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy.

Hor H, Kutalik Z, Dauvilliers Y et al.

20711174 PubMed ID
GWAS Study Type
2129 Participants
90 Views
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

HH
Hor H
KZ
Kutalik Z
DY
Dauvilliers Y
VA
Valsesia A
LG
Lammers GJ
DC
Donjacour CE
IA
Iranzo A
SJ
Santamaria J
PA
Peraita Adrados R
VJ
Vicario JL
OS
Overeem S
AI
Arnulf I
TI
Theodorou I
JP
Jennum P
KS
Knudsen S
BC
Bassetti C
MJ
Mathis J
LM
Lecendreux M
MG
Mayer G
GP
Geisler P
BA
Benetó A
PB
Petit B
PC
Pfister C
BJ
Bürki JV
DG
Didelot G
BM
Billiard M
EG
Ercilla G
VW
Verduijn W
CF
Claas FH
VP
Vollenweider P
WG
Waeber G
WD
Waterworth DM
MV
Mooser V
HR
Heinzer R
BJ
Beckmann JS
BS
Bergmann S
TM
Tafti M
Chapter II

Abstract

Summary of the research findings

Narcolepsy is a rare sleep disorder with the strongest human leukocyte antigen (HLA) association ever reported. Since the associated HLA-DRB1*1501-DQB1*0602 haplotype is common in the general population (15-25%), it has been suggested that it is almost necessary but not sufficient for developing narcolepsy. To further define the genetic basis of narcolepsy risk, we performed a genome-wide association study (GWAS) in 562 European individuals with narcolepsy (cases) and 702 ethnically matched controls, with independent replication in 370 cases and 495 controls, all heterozygous for DRB1*1501-DQB1*0602. We found association with a protective variant near HLA-DQA2 (rs2858884; P < 3 x 10(-8)). Further analysis revealed that rs2858884 is strongly linked to DRB1*03-DQB1*02 (P < 4 x 10(-43)) and DRB1*1301-DQB1*0603 (P < 3 x 10(-7)). Cases almost never carried a trans DRB1*1301-DQB1*0603 haplotype (odds ratio = 0.02; P < 6 x 10(-14)). This unexpected protective HLA haplotype suggests a virtually causal involvement of the HLA region in narcolepsy susceptibility.

562 European ancestry cases, 702 European ancestry controls

Chapter III

Study Statistics

Key metrics and study information

2129
Total Participants
GWAS
Study Type
Yes
Replicated
370 cases, 495 controls
Replication Participants
European
Ancestry
Italy, Netherlands, Spain, France, Denmark, Germany, Switzerland
Recruitment Country
Chapter IV

AI-Generated Summary

AI-generated by DNAGENICS

Independent AI summary of health and genetic findings from the published study

Important: This summary is AI-generated by DNAGENICS for informational purposes only. It was not created by, affiliated with, or endorsed by the researchers behind the original publication, and is based solely on that published research. It may contain errors or omissions. DNAGENICS disclaims all liability for any inaccuracies or consequences arising from use of this information. Verify all information against the original publication. This is not professional scientific review or medical advice.

AI Summary In Progress

Our AI-generated summary of this publication is being prepared. Please check back soon.